Home >> Respiratory Devices >> Education >> Food & Beverage >>

Diphtheria Pipeline Review, H2 2012

Published: Oct-2012 | Format: PDF | Global Markets Direct | Number of pages: 70 | Code: MRS - 992

Global Markets Directs, 'Diphtheria Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diphtheria. Diphtheria Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope


A snapshot of the global therapeutic scenario for Diphtheria.
A review of the Diphtheria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Diphtheria pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Diphtheria.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diphtheria Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Diphtheria 9
Diphtheria Therapeutics under Development by Companies 11
Diphtheria Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Diphtheria Therapeutics Products under Development by Companies 18
Diphtheria Therapeutics Products under Investigation by Universities/Institutes 19
Companies Involved in Diphtheria Therapeutics Development 20
Sanofi-Aventis 20
GlaxoSmithKline plc 21
Merck & Co., Inc. 22
Takeda Pharmaceutical Company Limited 23
Novartis Vaccines and Diagnostics, Inc. 24
Zosano Pharma, Inc. 25
Green Cross Corporation 26
LG Life Sciences, Ltd 27
Panacea Biotec Limited 28
Diphtheria Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
TdaP Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Act-HIB reconstituted with TRIPACEL - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Tdap Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GSK-217744 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
DTP-HepB-Polio-Hib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Quadracel - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DtwP-HB-Hib (liq) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DTP-HepB/Hib Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
V-419 + Prevnar 13 + RotaTeq - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 47
Hexaxim - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GC-1107 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Pentavalent DTwP-HepB-Hib Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KD-332 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Easysix - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TAK-361S - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Acellular Pertussis Vaccine + Tetanus-Diphtheria Booster Vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Diptheria Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Diphtheria Therapeutics Drug Profile Updates 57
Diphtheria Therapeutics Discontinued Products 60
Diphtheria Therapeutics - Dormant Products 61
Diphtheria Product Development Milestones 62
Featured News & Press Releases 62
Jun 22, 2012: Sanofi Pasteurs Hexaxim Receives Positive Opinion From European Medicines Agency 62
Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 63
Apr 21, 2011: Merck And Sanofi Pasteur Initiate Phase III Study In The United States Of Pediatric Combination Vaccine To Help Prevent Six Infectious Diseases 63
Apr 11, 2011: Arbor Pharmaceuticals Acquires Erythromycin Products From Abbott Laboratories 64
Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 64
Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 65
Jan 30, 2008: GlaxoSmithKline Launches Two New Innovative Vaccines 66
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 66
Jun 13, 2005: U.S. FDA Licenses sanofi pasteurs ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 67
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 67

Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Tables

Number of Products Under Development for Diphtheria, H2 2012 9
Products under Development for Diphtheria Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Sanofi-Aventis, H2 2012 20
GlaxoSmithKline plc, H2 2012 21
Merck & Co., Inc., H2 2012 22
Takeda Pharmaceutical Company Limited, H2 2012 23
Novartis Vaccines and Diagnostics, Inc., H2 2012 24
Zosano Pharma, Inc., H2 2012 25
Green Cross Corporation, H2 2012 26
LG Life Sciences, Ltd, H2 2012 27
Panacea Biotec Limited, H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 34
Diphtheria Therapeutics Drug Profile Updates 57
Diphtheria Therapeutics Discontinued Products 60
Diphtheria Therapeutics Dormant Products 61 
List of Figures

Number of Products under Development for Diphtheria, H2 2012 9
Products under Development for Diphtheria Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Route of Administration, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Molecule Type, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 34

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing